[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Axillary Hyperhidrosis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 51 pages | ID: A473228A0DADEN

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Axillary Hyperhidrosis PIPELINE HIGHLIGHTS
Axillary Hyperhidrosis is one of the widely researched conditions during 2020 with 7 companies actively focusing on realizing pipeline’s potential. Development of Axillary Hyperhidrosis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Axillary Hyperhidrosis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Axillary Hyperhidrosis.

Good progress is anticipated during 2020 and 2021 with Axillary Hyperhidrosis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Axillary Hyperhidrosis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
The “Axillary Hyperhidrosis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Axillary Hyperhidrosis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Axillary Hyperhidrosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Axillary Hyperhidrosis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Axillary Hyperhidrosis DRUG PROFILES
Axillary Hyperhidrosis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Axillary Hyperhidrosis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Axillary Hyperhidrosis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Axillary Hyperhidrosis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 7 Axillary Hyperhidrosis companies including company overview, key snapshot, contact information, and their strategies on accelerating Axillary Hyperhidrosis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Atacama Therapeutics, Brickell Biotech Inc, Dermata Therapeutics LLC, Dermavant Sciences Inc, Dermira Inc, Medytox Inc, Revance Therapeutics Inc

  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Axillary Hyperhidrosis
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners

1.1 Axillary Hyperhidrosis- Disease overview
1.2 Axillary Hyperhidrosis- Market Size
1.3 Axillary Hyperhidrosis- Companies Involved


2.1 Axillary Hyperhidrosis Pipeline by Phase
2.2 Axillary Hyperhidrosis Pipeline by Mechanism of Action
2.3 Axillary Hyperhidrosis Pipeline by Route of Administration
2.4 Axillary Hyperhidrosis Pipeline- New Molecular Entities
2.5 Axillary Hyperhidrosis Pipeline- Orphan Drug Designation/ Special Designation


3.1 Current Status
3.2 Axillary Hyperhidrosis Drug Snapshot
3.3 Axillary Hyperhidrosis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Atacama Therapeutics Axillary Hyperhidrosis Pipeline Insights and Clinical Trials
4.2 Brickell Biotech Inc Axillary Hyperhidrosis Pipeline Insights and Clinical Trials
4.3 Dermata Therapeutics LLC Axillary Hyperhidrosis Pipeline Insights and Clinical Trials
4.4 Dermavant Sciences Inc Axillary Hyperhidrosis Pipeline Insights and Clinical Trials
4.5 Dermira Inc Axillary Hyperhidrosis Pipeline Insights and Clinical Trials
4.6 Medytox Inc Axillary Hyperhidrosis Pipeline Insights and Clinical Trials
4.7 Revance Therapeutics Inc Axillary Hyperhidrosis Pipeline Insights and Clinical Trials



6.1 Sources and Methodology
6.2 Contact Information

More Publications